Patients with close (≤1 mm) margins after pancreatic cancer surgery had worse survival than those with clear margins. Neoadjuvant chemotherapy, but not adjuvant chemotherapy, brought their survival close to that of patients with clear margins.
- Median overall survival was 15.0 vs 24.0 months for ≤1 mm vs >1 mm margins after upfront resection.
- Neoadjuvant chemotherapy raised median survival in ≤1 mm patients to 29.4 months, vs 19.6 months with upfront surgery.
- Retrospective cohort of 110 patients, with an external CT radiomics model (AUC 0.72–0.77) to predict close margins before surgery.
This applies to pancreatic head cancer patients at high risk of close margins, identified by CT radiomics. It is a retrospective comparison, so it supports selecting patients for neoadjuvant chemotherapy, not a general switch to it.
Journal Article by Li M, Lin Y (…) Ke N et 8 al. in J Surg Oncol
© 2026 Wiley Periodicals LLC.